Wire · opportunities
FDA rejects cancer therapy positioned to rival Novartis treatment
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 13 August 2026 · Fusion42 review
The FDA has rejected ITM Isotope Technologies Munich's radiopharmaceutical therapy ITM-11 for gastroenteropancreatic neuroendocrine tumors due to chemistry, manufacturing, and controls issues, despite the drug showing promising clinical trial results.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your cancer biotech faces stricter manufacturing scrutiny from the FDA that could delay market entry even with strong clinical data. Fixing these operational gaps now can turn rejection into a second chance to compete with Novartis.
◆ Coverage
1 source · 13 Aug 2026
◆ Related on Wire
◆ Topics
BiotechFDAcancer-therapydrug-approvalradiopharmaceuticalclinical-trials